Inhibition of the Growth of Patient-Derived Pancreatic Cancer Xenografts with the MEK Inhibitor Trametinib Is Augmented by Combined Treatment with the Epidermal Growth Factor Receptor/HER2 Inhibitor Lapatinib

Mutations of the oncogene KRAS are important drivers of pancreatic cancer progression. Activation of epidermal growth factor receptor (EGFR) and human EGFR2 (HER2) is observed frequent in pancreatic adenocarcinomas. Because of co-activation of these two signaling pathways, we assessed the efficacy o...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Walters, Dustin M, Lindberg, James M, Adair, Sara J, Newhook, Timothy E, Cowan, Catharine R, Stokes, Jayme B, Borgman, Cheryl A, Stelow, Edward B, Lowrey, Bryce T, Chopivsky, Maria E, Gilmer, Tona M, Parsons, John T, Bauer, Todd W
Format: Artigo
Langue:Inglês
Publié: Neoplasia Press Inc. 2013
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3579317/
https://ncbi.nlm.nih.gov/pubmed/23441129
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires